Arcutis加拿大子公司近日宣布,其Przoryve乳膏(0.05%浓度)已获得加拿大卫生部的上市许可,适用于2至5岁患有轻度至中度特应性皮炎的儿童患者。这一批准标志着该疗法在儿科皮肤治疗领域的重要进展。
Arcutis加拿大子公司近日宣布,其Przoryve乳膏(0.05%浓度)已获得加拿大卫生部的上市许可,适用于2至5岁患有轻度至中度特应性皮炎的儿童患者。这一批准标志着该疗法在儿科皮肤治疗领域的重要进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.